Open access · OA via Europe PMC

A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment.

Martens CR, Decker KP, DeConne TM, Sanjana F, Horvat F, Rizzi NA, Awad C, Habash E, Hobson JC, Kramer MK, Armstrong ML, Reisdorph N, Pohlig RT, Lanzi AM, Johnson CL

Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

Dysbiosis Human Randomized controlled trial

＋ Sign in to save

Abstract

<h4>Introduction</h4>Declining nicotinamide adenine dinucleotide (NAD<sup>+</sup>) may elevate risk of Alzheimer's disease.<h4>Methods</h4>We conducted a 12-week double-blind, randomized, placebo-controlled pilot study to evaluate the safety, tolerability, and preliminary efficacy of the NAD<sup>+</sup> precursor, nicotinamide riboside (NR), for enhancing cognitive function and cerebral blood flow (CBF) in adults with amnestic mild cognitive impairment (aMCI).<h4>Results</h4>42 participants completed the study (NR = 22, placebo = 20). Adherence was similar between groups with no serious adverse effects. Blood NAD<sup>+</sup> increased twofold in the NR group. There were no improvements in cognitive function (primary outcome), total CBF, or blood pressure (secondary outcomes). Exploratory analyses revealed potential increases in regional CBF, particularly in the hippocampus.<h4>Discussion</h4>NR effectively raises NAD<sup>+</sup> in people with MCI but does not improve cognitive function, total CBF, or blood pressure over 12 weeks. Future studies should investigate regional effects on CBF over longer treatment durations.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: Europe PMC
DOI: 10.1002/alz.71605
Canonical: link ↗
Fetched: 2026-10-07 MST

Cite this

APA

CR, M., KP, D., TM, D., F, S., F, H., NA, R., C, A., E, H., JC, H., MK, K., ML, A., N, R., RT, P., AM, L., CL, J., ML, C., & JM., E. (2026). A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment. <em>Alzheimer's & dementia : the journal of the Alzheimer's Association</em>. https://doi.org/10.1002/alz.71605

Vancouver

CR M, KP D, TM D, F S, F H, NA R, et al. A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. doi:10.1002/alz.71605.

BibTeX

@article{martens2026Aphase, title = {A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment.}, author = {Martens CR and Decker KP and DeConne TM and Sanjana F and Horvat F and Rizzi NA and Awad C and Habash E and Hobson JC and Kramer MK and Armstrong ML and Reisdorph N and Pohlig RT and Lanzi AM and Johnson CL and Cohen ML and Ellison JM.}, journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association}, year = {2026}, doi = {10.1002/alz.71605}, }